Osteoporosis drug may help cut risk of bone fractures, breast cancer, stroke
February 25th, 2010 - 2:15 pm ICT by ANILondon, Feb 25 (ANI): The nonsteroidal selective estrogen-receptor modulator lasofoxifene may help reduce the risk of vertebral and non-vertebral fractures, ER-positive breast cancer, coronary heart disease and stroke in postmenopausal women with osteoporosis, says a new study.
The research has been published in the latest issue of the New England Journal of Medicine.
Lasofoxifene has been shown to decrease bone loss and bone weakening, and reduce cholesterol levels, all common problems in postmenopausal women. However, its impact on other health issues for this population was not well understood.
“This is the first SERM that reduces the risk of all of these conditions at once,” says Steven Cummings, M.D., of the San Francisco Coordinating Center at the California Pacific Medical Center Research Institute, and the lead author of the study. “Not only did it reduce vertebral fractures, which was not unexpected, it also reduced the risk of non-vertebral fractures - injuries to the arms, legs, ribs, hips - that are the most common injuries to people with osteoporosis and the main causes of disability.”
To reach the conclusion, researchers followed 8,556 women, ages 59 to 80, over the course of 5 years. Two thirds of the women were given a daily dose of lasofoxifene (either 0.25mg or 0.5mg) and the other third were given a placebo.
The women were given lateral spine radiographs at 12, 24, 36, and 60 months to measure bone density and identify possible fractures. The women also underwent annual mammograms and clinical breast exams to detect breast cancer.
At the end of the five years patients who took lasofoxifene experienced fewer vertebral fractures than the placebo group - a 58 percent reduction in the patients taking 0.5mg a day and 31 percent in the lower dose group - and non-vertebral fractures (24 percent and 10 percent respectively). Those taking lasofoxifene also experienced increases in bone density compared to the placebo group.
Patients taking lasofoxifene experienced a reduction in their risk of estrogen receptor (ER) positive breast cancer (81 percent and 48 percent respectively), and a reduction in LDL (the so-called bad) cholesterol of around 16 percent.
The researchers say the results were not all positive. Patients taking lasofoxifene were at higher risk of experiencing a venous thromboembolic event or blood clot. (ANI)
- Drug counters bone-damaging effects of breast cancer medication - Oct 10, 2011
- Use of nitrates increases bone strength: study - Feb 23, 2011
- Fracture prone? Blame your genes - Apr 22, 2012
- Soy food safe for breast cancer survivors - Apr 06, 2011
- Estrogen alone can cut risk of breast cancer - Dec 10, 2010
- Postmenopausal hormone therapy 'ups breast cancer risk' - Oct 20, 2010
- Gene combinations linked to hip osteoporosis in postmenopausal women - Mar 30, 2011
- Soy intake lowers breast cancer recurrence in hormone-sensitive cancers - Oct 19, 2010
- Bone loss drugs may cut breast cancer risk - Mar 03, 2010
- Multiple childbirth linked to increased risk of 'triple-negative' breast cancer - Feb 25, 2011
- Body fat distribution linked to a higher risk of ER-negative breast cancer - Dec 16, 2010
- Hot flushes tied to lower risk of breast cancer - Jan 26, 2011
- Bone drug may help fight breast cancer - Jun 03, 2010
- Breast cancer survivors 'more likely to fall' - Mar 05, 2011
- Female sex hormone regulates weight - Oct 20, 2011
Tags: bone density, bone fractures, breast cancer, california pacific medical, california pacific medical center, cholesterol levels, clinical breast exams, coronary heart disease, dose group, england journal of medicine, london feb, medical center research, medical center research institute, new england journal, new england journal of medicine, osteoporosis drug, pacific medical center, placebo group, steven cummings, vertebral fractures